Building a Successful Infection Prevention Program: Key Components, Processes, and Economics

Infectious Disease Clinics of North America

Volumn 25, Issue 1, 2011, Pages 1-19

  Cook, Evelyn ^a   Marchaim, Dror ^b   Kaye, Keith S ^b  

^a DUKE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HAIs; Infection control; Infection prevention; Program

Indexed keywords

ACCREDITATION; BUDGET; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; PATIENT SAFETY; RESPONSIBILITY; REVIEW; TUBERCULOSIS;

COST-BENEFIT ANALYSIS; CROSS INFECTION; DISEASE OUTBREAKS; HOSPITALS; HUMANS; INFECTION CONTROL; RISK MANAGEMENT;

EID: 79551698655     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.11.007     Document Type: Review

References (70)

1. Scott RD. The direct medical cost of healthcare associated infections in US hospitals and the benefits of prevention. In: Prevention CfDCa, editor. 2009. Available at: Accessed November 3, 2010. http://www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf.
2. Yokoe D.S., Mermel L.A., Anderson D.J., et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol 2008, 29(Suppl 1):S12-S21.
3. Occupational exposure to bloodborne pathogen-OSHA. Final rule. Fed Regist 1991, 56:64004. Standard 1910.1030.
4. Occupational exposure to tuberculosis. Fed Regist 2003, 68:75767-75775. Standard 1910;12/31/2003:OSHA.
5. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. In: (HICPAC) CfDCaP-HICPAC, editor. 2007. Available at: Accessed November 3, 2010. http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html.
6. Saving 100,000 lives campaign Available at:, Accessed November 3, 2010. http://www.ihi.org/IHI/Programs/Campaign/.
7. Protecting 5 millions lives from harm Available at:, Accessed November 3, 2010. http://www.ihi.org/IHI/Programs/Campaign/.
8. Infection control related sentinel events Available at:, Accessed January 22, 2003. http://www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_28.htm.
9. 2004 National Patient Safety Goals Available at:, Accessed November 3, 2010. http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/2004_npsgs.htm.
10. Gourley D. Joint Commission places infection control under the microscope. 2004. Available at: Accessed November 3, 2010. http://www.highbeam.com/doc/1G1-139951600.html.
11. The Joint Commission Hospital accreditation program: 2009 National Patient Safety Goals. Reduce the risk of healthcare associated infections 2009, The Joint Commission, Oakbrook Terrace (IL), p. 11-7. Available at:, Accessed November 3, 2010. http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/09_npsgs.htm.
12. Conditions for coverage- infection control. Fed Regist 2008;73(223). Availabe at: Accessed November 3, 2010. http://www.access.gpo.gov/su_docs/fedreg/a081118c.html.
13. Assessing risk is a starting point, vol. IC.01.03.01. 2009.
14. Friedman C. Infection prevention and control programs. APIC text of infection control and epidemiology 2009, vol. 1. 3rd edition. APIC, Washington, DC, p. 1-4. R. Carrico (Ed.).
15. Strausbaugh L.J. Anxiety on the watchtower: the hospital epidemiologist and emerging infectious diseases. Curr Infect Dis Rep 2003, 5(6):451-453.
16. Nutty C. Project management and communication. Certification study guide 2007, APIC, Available at:, Accessed November 3, 2010. http://ecdc.europa.eu/ipse/Working%20packages/WP1/Core%20Curriculum%20Report.pdf, 3rd edition.
17. Haley R.W., Quade D., Freeman H.E., et al. The SENIC project. Study on the efficacy of nosocomial infection control (SENIC project). Summary of study design. Am J Epidemiol 1980, 111(5):472-485.
18. Stone P.W., Dick A., Pogorzelska M., et al. Staffing and structure of infection prevention and control programs. Am J Infect Control 2009, 37(5):351-357.
19. Gaynes R., Richards C., Edwards J., et al. Feeding back surveillance data to prevent hospital-acquired infections. Emerg Infect Dis 2001, 7(2):295-298.
20. Hospital interpretive guidelines, vol. 42 CFR 482.42 (a)(2) 2008, Department of Health & Human Services (DHHS) Centers for Medicare and Medicaid, Available at:, Accessed November 3, 2010. http://www.cms.gov/manuals/downloads/som107ap_a_hospitals.pdf.
21. Patient safety component protocol: National Healthcare Safety Network (NHSN) Manual. 2008. Available at: Accessed November 3, 2010. http://www.dhcs.ca.gov/provgovpart/initiatives/nqi/Documents/NHSNManPSPCurr.pdf.
22. Arias K.M. Surveillance. APIC text of infection control and epidemiology 2009, vol. 1. 3rd edition. APIC, Washington, DC, p. 3-5. R. Carrico (Ed.).
23. Greene L., Cain T.A., Khoury R. APIC position paper: the importance of surveillance technologies in the prevention of healthcare-associated infections. Am J Infect Control 2009, 37(6):510-513.
24. Srinivasan Outbreak investigation. APIC text of infection control and epidemiology 2009, vol. 1. 3rd edition. APIC, Washington, DC, p. 1-4. R. Carrico (Ed.).
25. Nadzam D., Soule B. Performance measures. APIC text of infection control and epidemiology 2009, vol. 1. 3rd edition. APIC, Washington, DC, p. 1-9. R. Carrico (Ed.).
26. Altpeter T. Quality concepts. APIC text of infection control and epidemiology 2009, vol. 1. 3rd edition. APIC, Washington, DC, p. 1-8. R. Carrico (Ed.).
27. Perencevich E.N., Stone P.W., Wright S.B., et al. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol 2007, 28(10):1121-1133.
28. Fraser V.J., Olsen M.A. The business of health care epidemiology: creating a vision for service excellence. Am J Infect Control 2002, 30(2):77-85.
29. Maragakis L.L., Perencevich E.N., Cosgrove S.E. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6(5):751-763.
30. Murphy D.M. From expert data collectors to interventionists: changing the focus for infection control professionals. Am J Infect Control 2002, 30(2):120-132.
31. Burke J.P. Infection control - a problem for patient safety. N Engl J Med 2003, 348(7):651-656.
32. Calfee D.P., Farr B.M. Infection control and cost control in the era of managed care. Infect Control Hosp Epidemiol 2002, 23(7):407-410.
33. Freedberg K.A., Paltiel A.D. Cost effectiveness of prophylaxis for opportunistic infections in aids. An overview and methodological discussion. Pharmacoeconomics 1998, 14(2):165-174.
34. Davey P., Craig A.M., Hau C., et al. Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial. J Antimicrob Chemother 1999, 43(1):105-112.
35. Richter A., Brandeau M.L., Owens D.K. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Med Decis Making 1999, 19(2):167-179.
36. Reid R.J. A benefit-cost analysis of syringe exchange programs. J Health Soc Policy 2000, 11(4):41-57.
37. Walker D., Fox-Rushby J.A. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000, 9(8):681-698.
38. Wilkinson D., Floyd K., Gilks C.F. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa. S Afr Med J 2000, 90(8):794-798.
39. Lelekis M., Gould I.M. Sequential antibiotic therapy for cost containment in the hospital setting: why not?. J Hosp Infect 2001, 48(4):249-257.
40. Akalin H.E. Surgical prophylaxis: the evolution of guidelines in an era of cost containment. J Hosp Infect 2002, 50(Suppl A):S3-S7.
41. Floyd K., Blanc L., Raviglione M., et al. Resources required for global tuberculosis control. Science 2002, 295(5562):2040-2041.
42. Hutton G., Wyss K., N'Diekhor Y. Prioritization of prevention activities to combat the spread of HIV/AIDS in resource constrained settings: a cost-effectiveness analysis from Chad, Central Africa. Int J Health Plann Manage 2003, 18(2):117-136.
43. Kampf G. The six golden rules to improve compliance in hand hygiene. J Hosp Infect 2004, 56(Suppl 2):S3-S5.
44. Currie C.S., Floyd K., Williams B.G., et al. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 2005, 5:130.
45. Muniyandi M., Ramachandran R., Balasubramanian R. An economic commentary on the occurrence and control of HIV/AIDS in developing countries: special reference to India. Expert Opin Pharmacother 2006, 7(18):2447-2454.
46. Wilson A.P., Hodgson B., Liu M., et al. Reduction in wound infection rates by wound surveillance with postdischarge follow-up and feedback. Br J Surg 2006, 93(5):630-638.
47. Anderson D.J., Kirkland K.B., Kaye K.S., et al. Underresourced hospital infection control and prevention programs: penny wise, pound foolish?. Infect Control Hosp Epidemiol 2007, 28(7):767-773.
48. Graves N., Halton K., Lairson D. Economics and preventing hospital-acquired infection: broadening the perspective. Infect Control Hosp Epidemiol 2007, 28(2):178-184.
49. Perencevich E.N., Thom K.A. Commentary: preventing Clostridium difficile-associated disease: is it time to pay the piper?. Infect Control Hosp Epidemiol 2008, 29(9):829-831.
50. Kaye K.S. The financial impact of antibiotic resistance. What every health care executive should know: the cost of antibiotic resistance 2009, 29-42. Joint Commission Resources, Oakbrook Terrace (IL). B.M. Soule, S. Weber (Eds.).
51. 2006 APIC member salary and career survey Available at:, Accessed September 1, 2006. http://www.apic.org/Content/NavigationMenu/MemberServices/2006SalarySurveyResults/2006_Salary_Survey.htm.
52. Coskun D., Aytac J., Aydinli A., et al. Mortality rate, length of stay and extra cost of sternal surgical site infections following coronary artery bypass grafting in a private medical centre in Turkey. J Hosp Infect 2005, 60(2):176-179.
53. Rello J., Ollendorf D.A., Oster G., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122(6):2115-2121.
54. Carmeli Y., Troillet N., Karchmer A.W., et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999, 159(10):1127-1132.
55. Carmeli Y., Eliopoulos G., Mozaffari E., et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002, 162(19):2223-2228.
56. Cosgrove S.E., Kaye K.S., Eliopoulous G.M., et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162(2):185-190.
57. Cosgrove S.E., Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003, 36(11):1433-1437.
58. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36(5):592-598.
59. Cosgrove S.E., Qi Y., Kaye K.S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26(2):166-174.
60. Schwaber M.J., Navon-Venezia S., Kaye K.S., et al. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 2006, 50(4):1257-1262.
61. Giske C.G., Monnet D.L., Cars O., et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008, 52(3):813-821.
62. Warren D.K., Shukla S.J., Olsen M.A., et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31(5):1312-1317.
63. Hugonnet S., Eggimann P., Borst F., et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004, 25(12):1090-1096.
64. Blot S.I., Depuydt P., Annemans L., et al. N Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005, 41(11):1591-1598.
65. Coello R., Charlett A., Wilson J., et al. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005, 60(2):93-103.
66. Hollenbeak C.S., Murphy D.M., Koenig S., et al. The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. Chest 2000, 118(2):397-402.
67. Tambyah P.A., Knasinski V., Maki D.G. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol 2002, 23(1):27-31.
68. Lai K.K., Fontecchio S.A. Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. Am J Infect Control 2002, 30(4):221-225.
69. Ward W.J., Spragens L., Smithson K. Building the business case for clinical quality. Healthc Financ Manage 2006, 60(12):92-98.
70. Perencevich E.N., Fisman D.N., Lipsitch M., et al. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004, 38(8):1108-1115.